Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1

In this real-world study, CAB+RPV LA maintained high rates of virologic suppression, was well tolerated, and led to increased treatment satisfaction through 24 months following switch. These data reinforce the findings of the Phase 3/3b CAB+RPV LA program and support the continued use of CAB+RPV LA in routine clinical care.

Authors

Institutions

Publication Details

Journal
AIDS
Published
2026-01-20
DOI
https://doi.org/10.1097/qad.0000000000004448
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1

Bernd Westermayer, Kevin Ummard-Berger, Jenny Scherzer, Patricia Rios et al.
AIDS
HIV/AIDS drug development and treatment
article

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1

Bernd Westermayer, Kevin Ummard-Berger, Jenny Scherzer, Patricia Rios, Anja Potthoff, Jan Borch, Heribert Hillenbrand, Elena Rodriguez, Stefan Scholten, Niels Schübel, Sebastian Noe, Celia Jonsson-Oldenbüttel, Christoph Wyen, Lori A. Gordon, Kathrin M. Dymek
article en

Abstract

In this real-world study, CAB+RPV LA maintained high rates of virologic suppression, was well tolerated, and led to increased treatment satisfaction through 24 months following switch. These data reinforce the findings of the Phase 3/3b CAB+RPV LA program and support the continued use of CAB+RPV LA in routine clinical care.

AIDS
ViiV Healthcare (Spain) (ES), Friedrich-Ebert-Stiftung e.V. (DE), Goethe Institut (DE), Klinikum Osnabrück (DE), GlaxoSmithKline (Germany) (DE), Klinikum im Friedrichshain (DE), University Hospital Cologne (DE), Orthopädische Praxis (DE), Ruhr University Bochum (DE), Praxis (EE)
Good health and well-being
Openalex Percentile: Top 81%
HIV/AIDS drug development and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1 — Bernd Westermayer, Kevin Ummard-Berger, et al. · AIDS (2026) | TGRS Research Map | TGRS